The estimated Net Worth of Dana G Jr. Mead is at least $915 mil dollars as of 5 October 2020. Mr. Mead owns over 26,315 units of Intersect ENT Inc stock worth over $743,136 and over the last 10 years he sold XENT stock worth over $0. In addition, he makes $171,432 as Independent Director at Intersect ENT Inc.
Dana has made over 4 trades of the Intersect ENT Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 26,315 units of XENT stock worth $499,985 on 5 October 2020.
The largest trade he's ever made was buying 26,315 units of Intersect ENT Inc stock on 5 October 2020 worth over $499,985. On average, Dana trades about 1,503 units every 42 days since 2014. As of 5 October 2020 he still owns at least 26,315 units of Intersect ENT Inc stock.
You can see the complete history of Mr. Mead stock trades at the bottom of the page.
Dana G. Mead Jr. serves as Independent Director of the Company. He has served as a member of our Board of Directors since June 2007. Since May 2019, Mr. Mead has served as President and CEO of HeartFlow, Inc., a medical device company located in Redwood City, CA. From November 2016 to May 2019, Mr. Mead served as the President and Chief Executive Officer of Beaver-Visitec International, a medical device company located in Waltham, MA. Previously, Mr. Mead was a Strategic Advisor and Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, having joined the firm in May 2005. Mr. Mead was at Guidant Corporation, a cardiovascular medical device company, from 1992 to 2005, most recently as President, Guidant Vascular Intervention. Since January 2008, Mr. Mead has also served as a member of the board of directors of Inspire Medical Systems, Inc., a medical technology company. Mr. Mead has served on the board of directors of Teladoc, Inc., a telehealth platform company, from August 2011 to December 2016.
As the Independent Director of Intersect ENT Inc, the total compensation of Dana Mead at Intersect ENT Inc is $171,432. There are 8 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.
Dana Mead is 60, he's been the Independent Director of Intersect ENT Inc since 2006. There are 6 older and 6 younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.
Dana's mailing address filed with the SEC is C/O PULMONX CORPORATION, 700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063.
Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt, eW Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Intersect ENT Inc executives and other stock owners filed with the SEC include: